Home › All Companies › ANNX

Annexon, Inc. (ANNX)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-04-14

Key Insights

  • The filing reports that William H. Carson, a director of Annexon, Inc., acquired 8,000 shares of the company's common stock on April 10, 2026 at a price of $6.2 per share.
  • The acquisition was made pursuant to Carson's Rule 10b5-1 trading plan, which suggests a level of confidence in the company's long-term prospects.
  • With the additional 8,000 shares, Carson now beneficially owns a total of 70,405 shares of Annexon, Inc., indicating a significant personal investment in the company.
Sentiment: Positive Significance: 5/10
View Original Filing →
Current Report Filed: 2026-03-30

Key Insights

  • Annexon, Inc. announced its Q4 2025 and full-year 2025 financial results, providing visibility into the company's recent performance and upcoming milestones.
  • The filing does not indicate any material changes to Annexon's leadership or significant business agreements, suggesting a continuation of the company's current strategic initiatives.
  • Investors should monitor Annexon's progress on its portfolio of drug candidates and the achievement of anticipated milestones, which could impact the company's future growth and valuation.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Annual Report Filed: 2026-03-30

Key Insights

  • Annexon, Inc. filed its SEC 10-K report for the fiscal year 2025, indicating continued research and development efforts, as well as significant stock-based compensation expenses and financing activities.
  • The company appears to have implemented various stock option and incentive plans, including the 2022 Employment Inducement Award Plan and the 2022 Incentive Award Plan, to attract and retain talent.
  • Annexon reported entering into sales agreements with Cowen and Company, LLC for at-the-market equity offering programs in 2024 and 2026, potentially to raise additional capital for their operations.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-03-12

Key Insights

  • William H. Carson, a director of Annexon, Inc., purchased 8,000 shares of the company's common stock at $5.67 per share on March 10, 2026.
  • This insider buying transaction was made pursuant to a pre-existing Rule 10b5-1 trading plan, indicating a level of confidence in the company's prospects.
  • With this purchase, Carson's total beneficial ownership in Annexon increased to 62,405 shares, suggesting his alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-02-20

Key Insights

  • The reporting person, Dean Richard Artis, who is the EVP and Chief Scientific Officer of Annexon, Inc., sold 5,290 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.
  • The sale was executed at a weighted average price of $5.1 per share, with the shares being sold in multiple trades ranging from $4.925 to $5.155 per share.
  • Following the transaction, the reporting person continues to beneficially own 123,487 shares of Annexon's common stock.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Insider Trading Filed: 2026-02-20

Key Insights

  • The reporting person, Jennifer Lew, who is the EVP & Chief Financial Officer of Annexon, Inc. (ANNX), sold 7,851 shares of common stock on 02/18/2026 at an average price of $5.11 to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
  • The sale of shares by the CFO may indicate a short-term liquidity need, but the transaction appears to be routine and does not necessarily signal a broader negative outlook on the company's prospects.
  • The reporting person continues to hold 113,765 shares of Annexon, Inc. common stock, suggesting she maintains a significant ownership stake in the company.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-20

Key Insights

  • The reporting person, Jamie Dananberg, who is the Chief Medical Officer of Annexon, Inc., sold 5,290 shares of the company's common stock on February 18, 2026 to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
  • The sale price ranged from $4.93 to $5.16 per share, with a weighted average sale price of $5.10 per share.
  • Following the reported transaction, the reporting person beneficially owns 73,152 shares of Annexon's common stock.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-20

Key Insights

  • The reporting person, Michael Overdorf, who is the EVP & Chief Business Officer of Annexon, Inc. (ANNX), sold 6,225 shares of common stock on 2/18/2026 to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
  • The sale was executed in multiple trades at a weighted average price of $5.10, with the prices ranging from $4.93 to $5.16.
  • Following the reported transaction, the reporting person now beneficially owns 124,464 shares of Annexon's common stock.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Insider Trading Filed: 2026-02-20

Key Insights

  • The reporting person, Ted Yednock, sold 7,857 shares of Annexon, Inc. (ANNX) common stock on February 18, 2026 to cover tax withholding obligations related to the vesting of restricted stock units.
  • The sale price ranged from $4.925 to $5.17 per share, with a weighted average sale price of $5.11 per share.
  • Following the reported transaction, the reporting person continues to beneficially own 97,227 shares of Annexon, Inc. common stock.
Sentiment: Neutral Significance: 4/10
View Original Filing →
Current Report Filed: 2026-01-14

Key Insights

  • Annexon, Inc. has updated its corporate presentation to reflect certain business and strategic updates, which may be used in upcoming meetings with analysts and investors.
  • The company is presenting at the 44th Annual J.P. Morgan Healthcare Conference, indicating its continued engagement with the investor community.
  • The presentation will be available on the company's website, providing investors with easy access to the latest information.
Sentiment: Positive Significance: 5/10
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • Annexon is accelerating its next-generation targeted immunotherapy platform to treat neuroinflammatory diseases, with multiple registrational milestones planned for 2026.
  • The company's press release indicates a strategic priority to advance its lead programs, which could lead to potential new treatment options for patients suffering from neuroinflammatory conditions.
  • Investors should monitor Annexon's progress in achieving these key milestones over the next year, as they could significantly impact the company's long-term growth trajectory.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-02

Key Insights

  • The reporting person, William H. Carson, is a director of Annexon, Inc. and has purchased 4,115 shares of the company's common stock at $5.02 per share.
  • The insider transaction was made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2025, indicating a pre-planned nature of the purchase.
  • The reporting person now holds a total of 54,405 shares of Annexon's common stock, representing a direct ownership position.
Sentiment: Positive Significance: 5/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.